- Research Article
- Open Access
The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo
Journal of Hematology & Oncology volume 8, Article number: 82 (2015)
Combination therapy is a key strategy for minimizing drug resistance, a common problem in cancer therapy. The microtubule-depolymerizing agent vincristine is widely used in the treatment of acute leukemia. In order to decrease toxicity and chemoresistance of vincristine, this study will investigate the effects of combination vincristine and vorinostat (suberoylanilide hydroxamic acid (SAHA)), a pan-histone deacetylase inhibitor, on human acute T cell lymphoblastic leukemia cells.
Cell viability experiments were determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay, and cell cycle distributions as well as mitochondria membrane potential were analyzed by flow cytometry. In vitro tubulin polymerization assay was used to test tubulin assembly, and immunofluorescence analysis was performed to detect microtubule distribution and morphology. In vivo effect of the combination was evaluated by a MOLT-4 xenograft model. Statistical analysis was assessed by Bonferroni’s t test.
Cell viability showed that the combination of vincristine and SAHA exhibited greater cytotoxicity with an IC50 value of 0.88 nM, compared to each drug alone, 3.3 and 840 nM. This combination synergically induced G2/M arrest, followed by an increase in cell number at the sub-G1 phase and caspase activation. Moreover, the results of vincristine combined with an HDAC6 inhibitor (tubastatin A), which acetylated α-tubulin, were consistent with the effects of vincristine/SAHA co-treatment, thus suggesting that SAHA may alter microtubule dynamics through HDAC6 inhibition.
These findings indicate that the combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway. These data suggest that the combination effect of vincristine/SAHA could have an important preclinical basis for future clinical trial testing.
Microtubules, dynamically structured polymers of α-tubulin and β-tubulin, are required in many cellular processes, including vesicle and organelle transportation, cellular motility, cell shape maintenance, chromosome separation, and division . Before cells divide, microtubule-like reticular structures spread in the cytosol. As the cell enters the M phase, however, the original reticular microtubules are remodeled and assembled into mitotic spindles, which connect with chromosomes and drive chromosome separation . All of the microtubule processes described above are crucial for microtubule polymerization (stabilization) and depolymerization (destabilization).
Drugs that inhibit microtubule dynamics have been used clinically in cancer treatment for more than 20 years . These agents can be divided into two major types: microtubule-destabilizing agents, such as vincristine, and microtubule-stabilizing agents, such as paclitaxel . At lower concentrations, both types affect only microtubule dynamics, inducing abnormal mitotic spindle formation and causing cell arrest in the M phase and, subsequently, cell apoptosis . Microtubule-binding agents have played critical roles in the history of chemotherapeutic drug development and remain a first choice in the treatment of solid tumors and hematological malignancies. As with other anticancer agents, however, the problems of drug resistance, neuropathy, immunosuppression, and poor solubility must be addressed. The current trends in tubulin-binding agent development are to change the dosage to improve solubility or a combination of these agents with other anticancer drugs to reduce toxicity and enhance activity .
Histone deacetylase (HDAC) catalyzes the removal of the acetyl group in histones and nonhistone proteins. HDACs have different biological functions due to the highly divergent sequences outside the catalytic domain . HDAC6, which predominates in the cytoplasm , is responsible for tubulin deacetylation, which plays a key regulatory role in the stability of the dynamic microtubules [9–12]. HDAC overexpression in many cancers has also been reported [13–15]. Thus, HDAC is believed to be a promising target for cancer therapy . HDAC inhibitors (HDACis) cause histone hyperacetylation, thus activating the silenced gene for normal cellular function (cell cycle, angiogenesis, immunoregulation, cell apoptosis) . In addition, HDACis have been found to target nonhistone proteins, including protein 53 (p53), E2F1, signal transducer and activator of transcription 1, nuclear factor-κβ, α-tubulin, heat shock protein 90, and Ku 70 [18–20]. Suberoylanilide hydroxamic acid (SAHA), a pan-HDACi, was the first HDACi approved by the FDA for cutaneous T cell lymphoma in 2006 [21–23]. Owing to their low toxicity and wide range of activity, HDACis are often combined with other anticancer drugs . Most studies have been performed using cell-based experiments , but many combination therapies are undergoing clinical trials, often for hematological malignancies .
The purpose of this study is to evaluate the combined effects of vincristine and SAHA on an acute T cell lymphoblastic leukemia (ALL) model. We determined the mechanism underlying cell arrest in the mitotic phase and subsequent apoptosis following combination treatment. We found that vincristine and SAHA have a synergic effect on microtubules through different mechanisms. Moreover, this combined influence was also observed in in vivo results. Consequently, we suggest that a vincristine and SAHA combination treatment could be used in the clinical setting.
Cytotoxic effects of vincristine and SAHA, alone and in combination, on human leukemic MOLT-4 cells
A 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay was performed to investigate the cytotoxicity of the microtubule-destabilizing agent vincristine and the HDACi vorinostat (SAHA) on human ALL MOLT-4 cells. We first tested the cytotoxic effect of SAHA and vincristine alone and in combination. As shown in Fig. 1a, there was no significant cytotoxicity at concentrations up to 500 nM of SAHA. However, SAHA had an IC50 of 840 nM for 48 h, when concentration reached the highest level (1000 nM). In addition, vincristine exhibited cytotoxicity against human leukemic MOLT-4 cells with an IC50 of 3.3 nM at 48 h (Fig. 1b). To determine whether an interaction between SAHA and vincristine took place, the cytotoxic potency of a combination assay was measured. Cells treated with 500 nM SAHA and various concentrations of vincristine (0.3 to 3 nM) significantly inhibited cell survival compared to each treatment alone (Fig. 1c).
Effects of vincristine in combination with SAHA on human T cell leukemic cell survival
To further explore the synergistic cytotoxic effects, we determined the effects on cell cycle distribution. As compared with SAHA, treatment with vincristine induced an increase in the G2/M phase of the cell cycle. In particular, the combination of vincristine plus SAHA caused an almost complete arrest of cells in the G2/M phase following short-term treatment (24 h) and a subsequent induction in the sub-G1 phase following long-term treatment (48 h) (Fig. 2a). Figure 2b shows the statistical results. Next, the combination index (CI) method was used to evaluate the synergistic combinations . A CI value of >1.0, 1.0, and <1.0 indicates an antagonistic, additive, or synergistic interaction, respectively, between the drugs. In the G2/M phase, the CI values of vincristine (0.3, 1, and 3 nM) combined with 500 nM SAHA were 1.63, 0.72, and 0.32, respectively, and the CI values in the sub-G1 phase were 0.97, 0.77, and 0.28, respectively (Fig. 2c). And this synergistic combination effect also was noted in the other T cell leukemic cell line, CCRF-CEM (Fig. 2d), rather than in acute myeloid leukemic cells (Additional file 1: Figure S2). Moreover, vincristine (1 or 3 nM) combined with various concentrations of SAHA also shows synergistic effect (Additional file 2: Figure S1). These data indicate that vincristine and SAHA synergistically induced cell arrest in the G2/M phase and subsequently in the sub-G1 phase.
Effects of SAHA in combination with vincristine on mitotic arrest in human leukemic MOLT-4 cells
To further elucidate the synergistic effect mechanism on the G2/M phase of cell cycle progression, we investigated SAHA in combination with vincristine on tubulin polarization change and mitosis-related proteins. As shown in Fig. 3a, there were no obvious tubulin polarization changes following SAHA treatment under cell-free conditions. However, in combination with vincristine, a significant induction of microtubule depolymerization was observed (Fig. 3a). Additional file 3: Figure S3 shows a more comprehensive result, including various vincristine- and SAHA-alone in vitro tubulin polymerization assays. To understand the effects of microtubule dynamics on mitosis following drug treatment, the microtubule arrangement in human leukemic MOLT-4 cells was examined by β-tubulin staining. As shown in Fig. 3b(b), there was no significant change in microtubule distribution and cell morphology after SAHA treatment. In addition, at low vincristine concentrations, cells had accumulated at the metaphase stage of mitosis with abnormal spindles (Fig. 3b(c)). In this study, spindles with bipolar and multipolar organization, which had abnormal long astral microtubules and chromosomes, were found to be unequally distributed. Nevertheless, at a high vincristine concentration, microtubule depolymerization was observed (Fig. 3b(d)). In the present study, the vincristine and SAHA combination exerted more explicit effects than vincristine alone with regard to abnormal spindles and chromosomes (Fig. 3b and Additional file 4: Figure S4). These results suggest that SAHA potentiated the effects of vincristine due to inhibition of microtubule dynamics.
M phase-regulating proteins were also analyzed. The combination of various concentrations of vincristine (0.3, 1, and 3 nM) with SAHA (500 nM) for 24 h increased the phosphorylation of two mitotic markers (MPM2 and H3S10) in a concentration-dependent manner. These results proved that the combination of vincristine and SAHA induced M phase arrest. Moreover, vincristine in combination with SAHA also induced mitotic arrest by stimulating cyclin B1, aurora B, phospho-Cdc2 (Thr161), and phospho-PLK1 expression, and suppressing Cdc25c and phospho-Cdc2 (Tyr15) levels. The magnitude of these changes was more obvious than those observed with vincristine treatment alone (Fig. 3c). These findings demonstrate that SAHA enhanced vincristine-induced M phase arrest and that the combination therapy induced microtubule dynamics instability and mitotic activation.
Effects of SAHA in combination with vincristine on the apoptotic pathway and HDAC activity in human leukemic MOLT-4 cells
Mitochondria play a crucial role both in the intrinsic and extrinsic apoptotic pathways. To test whether the vincristine/SAHA-mediated apoptotic pathway was associated with mitochondrial function, a change in mitochondrial transmembrane potential (Δψm) was assessed. As shown in Fig. 4a, treatment with SAHA or vincristine alone was insufficient to affect the mitochondrial membrane potential; however, this phenomenon was enhanced by co-treatment with SAHA in a time-dependent manner. The Bcl-2 protein family plays a regulatory role in controlling the mitochondrial apoptotic pathway. The data showed that the combination treatment more effectively downregulated the expression of the pro-survival members of the Bcl-2 family, such as Bcl-2, Bcl-xl, and Mcl-1, than did either treatment alone (Fig. 4b).
Caspase activation plays an important role in the classic apoptotic pathways. In this study, it was also found that caspases 3, 6, 7, 8, and 9 and PARP were activated by the combination treatment for 48 h (Fig. 4c). Moreover, to confirm whether HDACs, both in the single or combination treatment, were involved in the apoptosis pathway, the expression of HDACs and H3 acetylation were evaluated. Vincristine (3 nM) in combination with SAHA effectively inhibited HDAC3 and HDAC6 expression and enhanced H3 acetylation, which represents an inhibition in HDAC activity, in a time-dependent manner (Fig. 4d).
HDAC6 inhibition was involved in vincristine/SAHA-induced apoptosis
Previous findings have shown HDAC6-induced tubulin acetylation to affect the dynamics and function of microtubules [9–12]. As shown in Fig. 5a, SAHA, a pan-HDACi, induced tubulin acetylation; however, its combination with vincristine had no synergic effect. Tubastatin A, which is a specific HDAC6 inhibitor , was used to understand the role of HDAC6 in the vincristine/SAHA-treated cells. To evaluate the potential benefit of vincristine in combination with tubastatin A, the cytotoxicity of co-treatment was determined and the combination effects were analyzed. However, compared to tubastatin A alone, vincristine significantly enhanced the cytotoxicity of tubastatin A (Fig. 5b). Moreover, vincristine (1 and 3 nM) combined with various concentrations of tubastatin A induced cell accumulation at the G2/M phase followed by the sub-G1 phase (Fig. 5c). The CI values were <1 in combination of vincristine and tubastatin at the G2/M phase and sub-G1 phase (Fig. 5d). Co-treatment of vincristine and tubastatin revealed MPM2 and PARP activation consistent with the induction of apoptosis by western blot analysis (Fig. 5e). And vincristine and HDAC6 inhibitor combined synergism effect was further corroborated by the observation of vincristine and ACY1215 co-treatment in CCRF-CEM cells (Fig. 5f). These findings suggest that SAHA treatment may alter microtubule dynamics in cells through HDAC6 inhibition, even though the effect was insufficient to arrest cells in the G2/M phase. However, in combination with vincristine, which also had an effect on microtubules, SAHA caused extreme microtubule stress thus causing cell death.
The antitumor activity of vincristine and SAHA combination therapy in vivo
To evaluate whether the synergistic effect of vincristine plus SAHA could be clinically relevant, the antitumor activity of this co-treatment in severe combined immunodeficiency mice bearing established MOLT-4 tumor xenografts was investigated. Once a tumor was palpable (approximately 100 mm3), mice were randomized into vehicle control and treatment groups (n = 6 per group). All mouse tumors were allowed to reach an endpoint volume of 2000 mm3, and in vivo antitumor efficacy was expressed as tumor growth delay (TGD; Fig. 6a). There were no improvements in TGD in mice treated with vincristine (0.1 mg/kg once weekly) or SAHA (50 mg/kg once daily) alone. However, log-rank analysis showed that the co-treatment exhibited significant antitumor activity in the MOLT-4 xenograft model (P = 0.0389). In addition, Kaplan–Meier curves displayed antitumor activity for the co-treatment group (vincristine, 0.025 mg/kg once weekly; SAHA, 200 mg/kg once daily) (Fig. 6b). Notably, the mice tolerated all of the treatments without overt signs of toxicity; no significant body weight difference or other adverse side effects were observed (Fig. 6d and Additional file 5: Figure S5). To correlate the in vivo antitumor effects with the mechanisms identified in vitro, intratumoral biomarkers were assessed by western blot analysis. Consistent with in vitro results, the combined treatment markedly induced caspase 3 activation and PARP cleavage in tumors, indicating elevated apoptosis (Fig. 6e). Taken together, these findings suggest that combination of vincristine and SAHA, both in vitro and in vivo, dramatically enhanced vincristine-induced cell death.
Recent preclinical studies have reported that due to their broad anticancer potency and low toxicity, HDACis are often used in combination therapy to enhance conventional chemotherapeutic and molecular-targeted drugs. SAHA was the first HDACi approved by the FDA for T cell lymphoma. Moreover, vinca alkaloids have been extensively used in the clinical treatment of ALL. In spite of their usefulness, drug resistance and neuron toxicity remain serious clinical problems. Therefore, the purpose of this study was to investigate the anticancer activity of vincristine and SAHA in a T cell ALL cell line. Cytotoxic experiments have shown that the combination of vincristine and SAHA significantly induces cell death. Analyses of cell cycle and regulatory protein expressions have indicated that co-treatment with the two drugs has a synergistic effect on M phase arrest and is consistent with an increase of cell numbers in the sub-G1 phase. Furthermore, combination treatment promotes cell apoptosis through intrinsic and extrinsic pathways. In vivo xenograft animal models demonstrated that, compared to treatment with either drug alone, vincristine in combination with SAHA prolongs survival time in mice, as suggested by the in vitro results.
During these studies, the level of the effects of vincristine and SAHA on MOLT-4 cells was determined. Combinations with various concentrations of both drugs were investigated to determine the lowest effective concentration of vincristine or SAHA that would provide the maximum cytotoxic effects. It was established that the cytotoxicity of 3 nM vincristine combined with 500 nM SAHA is much more potent in inhibiting cell survival (Fig. 1) and altering cell cycle distribution (Fig. 2) compared to either treatment alone. A CI value smaller than 1 at the G2/M or sub-G1 phases suggests that the combination of vincristine and SAHA had a synergistic action on T cell leukemic cells at certain concentrations (Fig. 2).
Prior studies have shown that α-tubulin acetylation is associated with microtubule dynamics and is regulated by HDAC6 . Additional research has also found that HDACis induce microtubule acetylation and polymerization through HDAC6 inhibition [9–12]. Whether the polymerization or the depolarization of microtubules following the vincristine and SAHA combination treatment was responsible for G2/M cell cycle arrest needs to be determined for a complete understanding of this mechanism. In vitro tubulin polymerization assays showed that a high concentration of vincristine (10 μM) definitely caused microtubule depolymerization, but a high concentration of SAHA (50 μM) had no influence on microtubule polymerization (Fig. 3a). However, SAHA indeed causes the acetylation of tubulin (Figs. 4d and 5a). These results suggest that SAHA may induce tubulin acetylation, subsequently affecting microtubule polymerization by inhibiting HDAC6 activity. Nevertheless, SAHA-induced polymerization was not proven (Fig. 3a) since HDAC6 was not available in the in vitro tubulin polymerization kits, which contained only tubulin and GTP. Therefore, no SAHA-induced polymerization effects were observed in this assay. In addition, the literature indicates that tubulin acetylated by certain HDACis, such as trichostatin A, is associated with microtubule dynamics without affecting the polymerization of microtubules. Therefore, to further demonstrate the role of HDAC6, tubastatin A, a specific HDAC6 inhibitor, was used [26–28]. Tubastatin A and vincristine co-treatment was found to synergically induce cell death and G2/M phase cell arrest, proceeding to the sub-G1 phase, compared with tubastatin A or vincristine alone (Fig. 5). These phenomena were in agreement with the results of vincristine/SAHA combination treatment. Consequently, an immunofluorescence assay was performed to demonstrate whether microtubules were affected by SAHA. Figure 3b shows that at low vincristine concentrations, abnormal spindles (star-like monopolar and multiple polars) and chromosome disorganization were observed, as has been previously reported by Jordan et al. . However, the microtubule distribution remained unchanged following cell treatment with 500 nM SAHA. However, following SAHA/vincristine combination treatment, more cells were observed to have deteriorated spindles although without microtubule depolymerization or polymerization. Prior studies have shown that only higher concentrations (>10 nM) of microtubule agents, such as vinca alkaloids and taxol, affect microtubule mass, but microtubule dynamics are suppressed by low microtubule agent concentrations (<10 nM) . Taken together, vincristine/SAHA-induced synergistic G2/M arrest may result from HDAC6 inhibition-induced microtubule dynamic alternation because of SAHA as well as vincristine. In brief, vincristine and SAHA exerted a synergic action on microtubule dynamics, albeit though different mechanisms.
A large amount of research shows that HDACis arrest cells in the G1 phase mainly through p21 induction. Only a few studies mention the role of these compounds in G2/M, and the mechanism remains uncertain. For example, Blagosklonny et al. found that the HDACi trichostatin A causes tubulin acetylation that contributes to M phase arrest . HDACis have also shown the capability to cause immature sister chromatid separation and slippage from the mitotic spindle assembly checkpoint (SAC) . Moreover, cancer cells without wild-type p21 or p53 more easily become polyploid than wild-type cells . These results indicate that HDACi-induced G2/M arrest is not due to an influence on transcriptional activity. In contrast, other studies point out that trichostatin A causes G2/M cell cycle arrest and SAC slippage through an increase in p21 transcriptional activity . The mechanisms proposed above to explain vincristine/SAHA-induced G2/M phase arrest should not be excluded. We found that p21 mRNA and protein level were elevated after treatment with vincristine or SAHA alone and was not enhanced by combined treatment (data not shown). It has been reported that all HDACis induced p21 but differentially caused tubulin acetylation, mitotic arrest, and cytotoxicity. Mitotic arrest rather than induction of p21 determined HDACi cytotoxicity . Moreover, p21 is required for G1 arrest, not for cell death, and is associated with resistance to HDACi-induced apoptosis . Upregulated p21 was also found in vincristine-treated cells even though vincristine caused cell arrest in the G2/M phase, leading to apoptosis . Therefore, we considered that in our study, increased p21 expression of vincristine-SAHA combined treatment was the cellular protection mechanism for repairing damaged DNA, and this phenomenon was not sufficient to cause apoptosis. Furthermore, vincristine and SAHA did not alter p53 protein and mRNA levels (data not shown). Consequently, the involvement of p53 and p21 in drug-induced G2/M arrest was eliminated.
The expression of related proteins in the M phase was evaluated to understand the exact phase at which the cells arrest (G2 or M). Cdc25c is a tyrosine phosphatase that removes the inhibitory phosphorylation of Cdc2 at Tyr15, which has already been phosphorylated on Thr161 and contributes to Cdc2 activation. The Cdc2/cyclin B complex then forms to move cells into the M phase . Figure 3c shows that Cdc25c and p-Tyr15 Cdc2 protein levels declined and p-Thr161 Cdc2 increased following combination treatment. In addition, expression of the M phase markers pMPM2 and H3S10 was also induced . These results demonstrate that combination treatment induces cell arrest in the M phase and not in G2.
From the above data, we speculate that the vincristine/SAHA combination may alter microtubule dynamics, resulting in incorrect microtubule attachment to the centromere of chromosomes or loss of spindle tension across kinetochore pairs, subsequently causing SAC activation in the metaphase. An increased aurora B and PLK kinase protein expression and aurora B kinase activity, detected by H3S10 expression downstream of aurora B, are shown in Fig. 3c. SAC activation inhibits anaphase-promoting complex/cytochrome activity and decreases cyclin B degradation to inter-anaphase to accomplish cell division. Cells proceed to apoptosis owing to an inability to repair the dysfunction . Therefore, we suggest that co-treatment-induced cell death was due to an inability to repair microtubule function even if the SAC was activated (Figs. 3c and 4c). In contrast, Dowling et al. have found that the synergistic effect of the HDACi trichostatin A and microtubule agents occurs through SAC inactivation . In addition, studies have shown that HDACis induce aurora B kinase degradation and subsequently inactivate the SAC via HDAC3 inhibition . Although HDAC3 is inhibited by 24-h vincristine and SAHA co-treatment (Fig. 4d), the protein level of aurora B kinase was increased (Fig. 3c). We believe that the arrest at the G2/M phase does not occur through the inhibition of HDAC3.
Caspase activation plays a vital role in the apoptosis pathways. Figure 4c shows that the activation of caspases 3 and 6 to 9 and PARP was synergistically induced by vincristine combined with SAHA. This result indicates that the combination treatment activates both the intrinsic and the extrinsic apoptosis pathways. Therefore, the expression of mitochondrial proteins and mitochondrial membrane potential were investigated. Bid is a key protein linking the extrinsic and intrinsic apoptosis pathways. As Fig. 4b shows, the protein level of pro-form Bid decreased in response to co-treatment with vincristine and SAHA. Decreases in pro-survival mitochondrial proteins Bcl-2, Bcl-xl, and Mcl-1 also occurred. A decrease in mitochondrial membrane potential was significantly induced by the combination in a time-dependent manner.
Taking all of the above findings into consideration, when vincristine and SAHA treatments were combined, MOLT-4 cell survival was significantly inhibited, mainly through the induction of M stage arrest and intrinsic and extrinsic apoptosis pathways. Moreover, the selective HDAC6 inhibitor exhibited similar synergism when combined with vincristine. In vivo xenograft animal models produced the same results as those of in vitro models. Pan-HDAC inhibitors influenced different types of HDACs, which caused side effects more than selective HDAC6 inhibitors. However, the most important and practical advantage to choose SAHA for this study is that SAHA has been approved for cancer treatment. Selective HDAC6 inhibitors such as tubastatin A and ACY1215 are only in phase I or phase II clinical trial. The finding of this paper not only provides another choice for clinical treatment but also offers an idea for the development and future application of HDAC6 inhibitors.
The human T cell acute lymphoblastic leukemic cell lines, MOLT-4 and CCRF-CEM, isolated from the relapsed and multiresistant patients, were obtained from Bioresource Collection and Research Center (Taiwan). Cells were maintained in RPMI-1640 medium supplemented with 10 % (v/v) fetal bovine serum (Gibco BRL Life Technologies, Grand Island, NY, USA) and 1 % of a mixture of penicillin (100 U/ml) and streptomycin (100 μg/ml, Biological Industries Ltd., Kibbutz Beit Haemek, Israel). All cells were cultured in an incubator in the presence of 5 % CO2 at 37 °C.
Chemicals and antibodies
Vincristine and suberoylanilide hydroxamic acid (SAHA) were purchased from Sigma Chemical Co. (St. Louis, MO, USA), and tubastatin A (HDAC6 inhibitor) was synthesized from Dr. Jing-Ping Liou (Taipei Medical University, Taiwan). The above drugs were dissolved in DMSO (dimethylsulfoxide) and then preserved at −20 °C. Rhodamine 123, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium, propidium iodide, anti-β-tubulin, FITC-conjugated anti-mouse IgG, and all of the other chemical reagents used in this study were purchased from Sigma Chemical (St. Louis, MO, USA) and of analytical grade. Primary antibodies against Cdc2 (pY15), aurora B, caspase 8, caspase 9, HDAC1, HDAC2, HDAC3, HDAC4, and Bid were all purchased from Cell Signaling Technology (Beverly, MA); cyclin B, Cdc25C, Cdc2, PARP, Mcl-1, Bcl-2, Bcl-xl, and secondary antibodies were purchased from Santa Cruz (Santa Cruz, CA, USA); MPM2 (pSer/Thr) and H3 (pS10) were purchased from Upstate Biotechnology (Lake Placid, NY, USA); PLK (pT210), caspase 6, and caspase 7 were purchased from BD Biosciences (San Jose, CA, USA); caspase 3 was purchased from Imgenex (San Diego, CA, USA); acetyl-histone 3 was purchase from Millipore (Billerica, MA, USA); and an internal control, GAPDH, was purchased from Novus Biologicals (Littleton, CO, USA). Vectashield® mounting medium with DAPI was purchased from Burlingame, CA, USA.
Cell viability assay
Cell viability was verified by MTT assay. Firstly, cells were seeded in a 24-well plate at a density of 4 × 105 cells/well in 1 ml culture medium and then treated with various concentrations of vincristine or SAHA alone or a combination of both for 24 and 48 h. After treatment with drugs, 100 μl MTT solution (0.5 mg/ml in phosphate-buffered saline (PBS)) per well was added to the 24-well plate in the dark and the plate was incubated at 37 °C. The mitochondrial dehydrogenase of viable cells reduced MTT (yellow) to insoluble formazan dyes (purple). One hour later, the crystal formazan dyes were dissolved in the extraction buffer (0.1 M sodium acetate buffer, 100 μl/well). The absorbance was spectrophotometrically analyzed at 550 nm by an ELISA reader (Packard, Meriden, CT, USA).
Flow cytometry analysis
Evolution of the cell cycle histogram was performed by flow cytometry analysis to detect the changes in DNA content. Cells (1 × 106) were seeded in a 6-well plate in 2 ml fresh medium and treated with graded concentrations of vincristine, SAHA, or combination for the indicated time. Then, cells were collected, washed with PBS and fixed with 70 % (v/v) ice cold ethanol at −20 °C for 30 min. The fixed cells were centrifuged to remove the ethanol, rinsed with PBS, resuspended in 0.1 ml DNA extraction buffer (0.2 M Na2HPO4-0.1 M citric buffer, pH 7.8) for 20 min, and subsequently stained with 500 μl PI solution (80 μg/ml propidium iodide, 100 μg/ml RNase A, and 1 % Triton X-100 in PBS) for 20 min at room temperature in the dark. Data were analyzed by FACScan Flow Cytometer and CellQuest software (Becton Dickinson).
In vitro tubulin polymerization assay
To determine the microtubule polymerization of the indicated drugs in a cell-free condition, CytoDYNAMIX Screen 03 Kit (Cytoskeleton Inc.) was performed. General tubulin buffer, GTP stock (100 mM), and tubulin protein (10 mg/ml) were all prepared well following the protocol. A 96-well plate was placed in the spectrophotometer to prewarm at 37 °C for 30 min before detection. Then preparing the iced tubulin polymerization (TP) buffer, all mentioned processes were needed on the ice. Next, the drugs (2 μl) were added into each Eppendorf included with 85 μl TP buffer. The drugs must include DMSO (the control group), paclitaxel (10 μΜ), and vincristine (10 μΜ). Paclitaxel and vincristine were used as positive controls. Paclitaxel would induce the microtubule polymerization; in contrast, vincristine would depolymerize the microtubules. Finally, 30 μl tubulin proteins was added into the Eppendorf and transferred to the prewarmed 96-well plate. The absorbance was measured by a spectrophotometer and recorded every 1 min for 30 min at 340 nm and 37 °C.
Microtubule distribution and morphology were detected by immunofluorescence. Cover slides were placed in the 24-well plate and coated with poly-d-lysine for 1 day at least to enhance the suspension cells attached to the cover slides. Cells were seeded into the 24-well plate (8 × 105 cells/well) and treated with vincristine, SAHA, or both drugs for 24 h. The following experiments were performed at room temperature. The cells were fixed with 8 % paraformaldehyde in PBS for 15 min. After washing with PBS for several times, the cells were permeabilized with 0.1 % Triton X-100 in PBS for 10 min. Then, the cells were rinsed with PBS for 10 min three times. For blocking, 3 % BSA in PBS was used. After 1 h, the cells were washed with PBS and incubated with a primary β-tubulin antibody (1:200) for 2 h and FITC-conjugated anti-mouse IgG antibody (1:200) for 2 h. The mounting medium, which contains DAPI stain, was dropped onto the slides, and cover slides were recovered to the slides. Images were detected and captured with the ZEISS LSM 510 META confocal microscope.
Western blot analysis
After the treatment, cells (106 cells/ml) were harvested. Whole cell pellets were washed twice with PBS, lysed in lysis buffer (50 mM Tris, pH 7.4; 150 mM NaCl; 1 % Triton X-100; 1 mM EDTA; 1 mM EGTA) supplemented with protease inhibitors (1 mM PMSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 mM sodium orthovanadate, and 1 mM NaF) for 30 min, and then centrifuged for 30 min at 13,000 rpm at 4 °C. Total protein content was quantified by BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL, USA). Equivalent amounts of proteins were separated into diverse percentages by SDS-PAGE and subsequently transferred onto PVDF membranes. The membranes were blocked with 5 % nonfat milk in PBS for 1 h at room temperature and incubated with primary antibody in PBST buffer (0.1 % Tween 20 in PBS) at 4 °C overnight. After washing the membranes with PBST, blots were developed with the corresponding HRP-conjugated secondary antibody diluted in 0.5 % nonfat milk in PBS for 1 h at room temperature. The membrane was washed frequently with PBST, and finally immunoreactive protein bands were displayed using an enhanced chemiluminescence detection kit (Amersham, Buckinghamshire, UK).
Mitochondrial membrane potential
Rhodamine 123 was used to evaluate mitochondrial membrane potential. Rhodamine 123 is a kind of cationic fluorescent dye, which localizes in the mitochondria. Loss of mitochondrial membrane potential is associated with a lack of rhodamine 123 retention and a decrease of fluorescence intensity. Cells were treated with vincristine, SAHA, or combination for the indicated time. Rhodamine 123 (final concentration 10 μM) was added and incubated for 30 min at 37 °C in the dark. Then, cells were harvested and rinsed with PBS. The fluorescence intensity was measured by FACScan Flow Cytometer and CellQuest software (Becton Dickinson).
Tumor xenograft model
A tumor xenograft model was used to estimate the combination effect of vincristine and SAHA in vivo. MOLT-4 cells were implanted (107 cells/ml) into severe combined immunodeficiency (SCID) mice. When the average tumor size reached 100 mm3, mice were treated with an indicated dosage of vincristine or SAHA alone or a combination of both. Mice were scarified until the average tumor size was larger than 2500 mm3. Then, tumors were resected and frozen for the western blot analysis to evaluate the effect of vincristine/SAHA combination in vivo. All animal experiments followed ethical standards, and protocols have been reviewed and approved by the Animal Use and Management Committee of National Taiwan University (IACUC Approval No.: 20100225).
All experiments were done independently three times and presented as mean values ± SD, and then assessed by Bonferroni’s t test. The animal experiments were determined by the Mann-Whitney test. P < 0.05 was considered statistically significant.
acute lymphoblastic leukemia
tumor growth delay
Pellegrini F, Budman DR. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest. 2005;23(3):264–73.
Honore S, Pasquier E, Braguer D. Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci. 2005;62(24):3039–56. doi:10.1007/s00018-005-5330-x.
Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as a target in oncology. Cancer Treat Rev. 2009;35(3):255–61. doi:10.1016/j.ctrv.2008.11.001.
Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9(10):790–803. doi:10.1038/nrd3253.
Gundersen GG, Cook TA. Microtubules and signal transduction. Curr Opin Cell Biol. 1999;11(1):81–94.
Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009;8(8):2086–95. doi:10.1158/1535-7163.mct-09-0366.
De Ruijter AJ, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370(Pt 3):737–49. doi:10.1042/bj20021321.
Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet. 2003;19(5):286–93. doi:10.1016/s0168-9525(03)00073-8.
Boyault C, Sadoul K, Pabion M, Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene. 2007;26(37):5468–76. doi:10.1038/sj.onc.1210614.
Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417(6887):455–8. doi:10.1038/417455a.
Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 2002;21(24):6820–31.
Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S, et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 2003;22(5):1168–79. doi:10.1093/emboj/cdg115.
Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004;59(2):177–89. doi:10.1002/pros.20022.
Wilson AJ, Byun DS, Popova N, Murray LB, L’Italien K, Sowa Y, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006;281(19):13548–58. doi:10.1074/jbc.M510023200.
Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004;5(5):455–63.
Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs. 2007;16(5):659–78. doi:10.1517/135437126.96.36.1999.
Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769–84. doi:10.1038/nrd2133.
Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 2001;293(5535):1653–7. doi:10.1126/science.1062374.
Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000;408(6810):377–81. doi:10.1038/35042612.
Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J. 2000;19(4):662–71. doi:10.1093/emboj/19.4.662.
Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov. 2007;6(1):21–2. doi:10.1038/nrd2227.
Luong QT, O’Kelly J, Braunstein GD, Hershman JM, Koeffler HP. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res. 2006;12(18):5570–7. doi:10.1158/1078-0432.ccr-06-0367.
Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009;280(2):201–10. doi:10.1016/j.canlet.2009.01.002.
Acharya MR, Sparreboom A, Venitz J, Figg WD. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol. 2005;68(4):917–32. doi:10.1124/mol.105.014167.
Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–81. doi:10.1124/pr.58.3.10.
Jordan MA, Thrower D, Wilson L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci. 1992;102(Pt 3):401–16.
Bulinski JC, Richards JE, Piperno G. Posttranslational modifications of alpha tubulin: detyrosination and acetylation differentiate populations of interphase microtubules in cultured cells. J Cell Biol. 1988;106(4):1213–20.
Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther. 2002;1(11):937–41.
Magnaghi-Jaulin L, Eot-Houllier G, Fulcrand G, Jaulin C. Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Res. 2007;67(13):6360–7. doi:10.1158/0008-5472.can-06-3012.
Xu WS, Perez G, Ngo L, Gui CY, Marks PA. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res. 2005;65(17):7832–9. doi:10.1158/0008-5472.can-04-4608.
Noh EJ, Lee JS. Functional interplay between modulation of histone deacetylase activity and its regulatory role in G2-M transition. Biochem Biophys Res Commun. 2003;310(2):267–73.
Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer. 2000;83(6):817–25. doi:10.1054/bjoc.2000.1327.
Shinwari Z, Manogaran PS, Alrokayan SA, Al-Hussein KA, Aboussekhra A. Vincristine and lomustine induce apoptosis and p21(WAF1) up-regulation in medulloblastoma and normal human epithelial and fibroblast cells. J Neuro-Oncol. 2008;87(2):123–32. doi:10.1007/s11060-007-9502-4.
Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004;23(16):2825–37. doi:10.1038/sj.onc.1207528.
Nowak SJ, Corces VG. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet. 2004;20(4):214–20. doi:10.1016/j.tig.2004.02.007.
Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? J Cell Sci. 2009;122(Pt 15):2579–85. doi:10.1242/jcs.039719.
Dowling M, Voong KR, Kim M, Keutmann MK, Harris E, Kao GD. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol Ther. 2005;4(2):197–206.
Eot-Houllier G, Fulcrand G, Watanabe Y, Magnaghi-Jaulin L, Jaulin C. Histone deacetylase 3 is required for centromeric H3K4 deacetylation and sister chromatid cohesion. Genes Dev. 2008;22(19):2639–44. doi:10.1101/gad.484108.
This study was supported by grants from the National Science Council of Taiwan (NSC 99-2628-B002-024-MY3).
The authors declare that they have no competing interests.
MWC performed almost all the experiments. MJL and JPL provided the HDAC6 inhibitor tubastatin A. YLC was responsible for preparing the materials. JCW and SLP designed the animal study. SLP and CMT organized the manuscript. All authors approved the final manuscript.
Shiow-Lin Pan and Che-Ming Teng contributed equally to this work.
Additional file 1: Figure S2.
The effect of vincristine and SAHA co-treatment in acute myeloid leukemic cell lines. (A) HL60 (acute promyelocytic leukemia) cells were co-treated with the indicated vincristine and SAHA, and the CI values of the sub-G1 phase were analyzed. (B) The cell viability of U937 (acute monocytic leukemia) after the indicated treatment. V, vincristine; S, SAHA; Tuba, tubastatin A.
Additional file 2: Figure S1.
The effect of vincristine combined with various doses of SAHA. (A) MOLT-4 cells were treated with various SAHA alone or combined with 1 and 3 nM vincristine for 48 h. The cell viability was evaluated by MTT assay. (B) The distribution of cell cycle after MOLT-4 cells were treated with various concentrations of SAHA alone or in combination with vincristine 1 or 3 nM for 24 and 48 h. The quantitative data are shown in the time course. (C) The combination effect on G2/M arrest (left figure) and apoptosis (right figure) were used by the combination index (CI).
Additional file 3: Figure S3.
The results of vincristine- (0.3 and 3 μM), or SAHA (5 and 50 μM) alone, or combination of both in vitro tubulin polymerization assay. (A) The figure shows more comprehensive results on in vitro tubulin polymerization, including paclitaxel (10 μM), vincristine (0.3, 3, and 10 μM), SAHA (S, 5 and 10 μM) alone, and SAHA combined with vincristine (S 50 + V 0.3 and S 5 + V3). (B) The absorbance of different drugs at the endpoint (30 min).
Additional file 4: Figure S4.
The quantity of abnormal spindles in vincristine alone compared to combination with SAHA. MOLT-4 cells were treated with SAHA (0.5 μM) and vincristine alone (3 nM) or co-treatment for 24 h and then stained with β-tubulin and DAPI. The figure shows the quantity of abnormal spindles by the immunofluorescence images.
Additional file 5: Figure S5.
The cell toxicity of normal cells after combination treatment. The cell viability (MTT assay) of (A) HUVEC (human umbilical vein endothelial cell) and (B) BEAS-2B (human bronchial epithelial cell) after co-treating with the indicated drugs for 48 h.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Chao, MW., Lai, MJ., Liou, JP. et al. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo . J Hematol Oncol 8, 82 (2015). https://doi.org/10.1186/s13045-015-0176-7